ArticleFrontiers in bioengineering and biotechnology2024
DSEception: a noval neural networks architecture for enhancing pneumonia and tuberculosis diagnosis.
Article in Frontiers in bioengineering and biotechnology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Pneumonia and tuberculosis are prevalent pulmonary diseases globally, each demanding specific care measures. However, distinguishing between these two conditions imposes challenges due to the high skill requirements for doctors, the impact of imaging positions and respiratory intensity of patients, and the associated high healthcare costs, emphasizing the imperative need for intelligent and efficient diagnostic methods. Method: This study aims to develop a highly accurate automatic diagnosis and classification method for various lung diseases (Normal, Pneumonia, and Tuberculosis). We propose a hybrid model, which is based on the InceptionV3 architecture, enhanced by introducing Deepwise Separable Convolution after the Inception modules and incorporating the Squeeze-and-Excitation mechanism. This architecture successfully enables the model to extract richer features without significantly increasing the parameter count and computational workload, thereby markedly improving the performance in predicting and classifying lung diseases. To objectively assess the proposed model, external testing and five-fold cross-validation were conducted. Additionally, widely used baseline models in the scholarly community were constructed for comparison. Result: In the external testing phase, the our model achieved an average accuracy (ACC) of 90.48% and an F1-score (F1) of 91.44%, which is an approximate 4% improvement over the best-performing baseline model, ResNet. In the five-fold cross-validation, our model's average ACC and F1 reached 88.27% ± 2.76% and 89.29% ± 2.69%, respectively, demonstrating exceptional predictive performance and stability. The results indicate that our model holds promise for deployment in clinical settings to assist in the diagnosis of lung diseases, potentially reducing misdiagnosis rates and patient losses. Conclusion: Utilizing deep learning for automatic assistance in the diagnosis of pneumonia and tuberculosis holds clinical significance by enhancing diagnostic accuracy, reducing healthcare costs, enabling rapid screening and large-scale detection, and facilitating personalized treatment approaches, thereby contributing to widespread accessibility and improved healthcare services in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.